Novoseven (Eptacog Alfa (Activated))

Eptacog alfa is a recombinant activated factor VII that binds to tissue factor at sites of vascular injury, directly activating factor X to Xa. This bypasses the need for factors VIII and IX, leading to rapid thrombin generation and clot formation to stop bleeding.

The dose of Novoseven is individualized and determined by the prescribing clinician based on the severity of bleeding, patient weight, and clinical response. Specific dosing regimens are outlined in the product labeling and should be followed under medical supervision.

Data on the use of Novoseven in pregnancy and lactation are limited. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the treating physician.

To order Novoseven, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and import documentation.

Novoseven is a recombinant activated factor VII that bypasses the need for factor VIII or IX, making it effective in patients with inhibitors. Traditional factor concentrates replace the missing factor but are ineffective when inhibitors are present. Thus, Novoseven offers a distinct therapeutic option for inhibitor‑positive hemophilia and certain acquired bleeding disorders.

Novoseven must be stored refrigerated at 2‑8 °C. It should be kept in its original packaging, protected from light, and must not be frozen or shaken. If temperature excursions occur, consult the product label before use.

Novoseven is supplied as a sterile injectable solution for intravenous administration. It is given by slow IV push or infusion under the supervision of a qualified healthcare professional, following aseptic technique and the dosing instructions provided by the prescriber.

The most serious risks include thromboembolic events such as deep‑vein thrombosis, stroke, or myocardial infarction, as well as disseminated intravascular coagulation and severe allergic reactions including anaphylaxis. Patients should be monitored closely for signs of thrombosis or hypersensitivity.

Novoseven is contraindicated in patients with known hypersensitivity to eptacog alfa or any of its excipients, and in individuals with a history of thromboembolic disease where the risk outweighs the benefit. It should also be avoided in patients receiving other pro‑coagulant agents unless specifically directed by a physician.